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Background: In breast cancer patients routine thromboprophylaxis is not recommended but individualized risk
assessment is encouraged. The incorporation of hypercoagulability biomarkers could increase the sensitivity of risk
assessment models (RAM) to identify patients at VTE risk. To this aim we investigated the impact of cancer-related
characteristics on hypercoagulability biomarkers.
Methods: Thrombin generation (TG) assessed with the Thrombogramme-Thrombinoscope®, levels of platelet
derived microparticles (Pd-MP) assessed with flow cytometry, procoagulant phospholid dependent clotting time
(PPL-ct) measured with a clotting assay and D-Dimers (were assessed in a cohort of 62 women with breast cancer
and in 30 age matched healthy women.
Results: Patients showed significantly higher TG, Pd-MP, D-Dimers levels and shortened PPL-ct compared to the
controls. The PPL-ct was inversely correlated with the levels of Pd-MP, which were increased in 97% of patients.
TG and D-Dimers were increased in 76% and 59% of patients respectively. In any stage of the disease TG was
significantly increased as compared to the controls. There was no significant difference of TG in patients with local,
regional of metastatic stage. There was no significant difference in Pd-MP or Pd-MP/PS+ between the subgroups of
patients with local or regional stage of cancer. Patients with metastatic disease had significantly higher levels of
Pd-MP and Pd-MP/PS+ compared to those with regional stage. The D-Dimers increased in patients with metastatic
stage. In patients on chemotherapy with less than 6 months since diagnosis TG was significantly higher compared
to those on chemotherapy who diagnosed in interval > 6 months. Patients with metastatic disease had significantly
higher levels of Pd-MP and D-Dimers compared to those with non-metastatic disease.
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Conclusion: In breast cancer patients the stage, the time elapsed since the diagnosis and the administration of
chemotherapy are determinants of cellular and plasma hypercoagulability. The levels and the procoagulant activity
of Pd-MP are interconnected with the biological activity and the overall burden of cancer. TG reflects the procoagulant
properties of both breast cancer and chemotherapy in the initial period of cancer diagnosis. Thus the weighted
incorporation of the biomarkers of cellular and plasma hypercoagulabilty in RAM for VTE might improve their
predictive value.
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modelBackground
The close association of cancer with hypercoagulability
and the risk of thrombosis have been recognized since
the 19th century [1-3]. The risk of venous thrombo-
embolism (VTE) is about 7-fold higher in cancer pa-
tients compared to controls [4,5]. VTE significantly
affects morbidity and is the second cause of mortality in
hospitalized cancer patients [6-9]. Many aspects of the
interplay between cancer and blood coagulation have
been elucidated by experimental, clinical and epidemio-
logical studies [10,11]. The histological type, the burden
of cancer cells, the stage of the disease, the use of
chemotherapy and the time since diagnosis are determi-
nants of the VTE risk [12].
Breast cancer is the commonest malignancy in women
and is considered to be associated with low VTE risk as
compared to other malignancies. In women with newly
diagnosed breast cancer the cumulative incidence of
VTE is less than 1% [10,12]. However VTE risk increases
by 4- to 6-fold during chemotherapy as well as in ad-
vanced stage or metastatic disease [13]. Routine admin-
istration of thromboprophylaxis is not recommended in
women with breast cancer undergoing adjuvant chemo-
therapy since there are no relevant clinical trials asses-
sing the efficacy and safety of antithrombotic agents in
this context [14]. However, expert consensus statements
encourage an individualized approach for the identifica-
tion of patients at risk of VTE who are eligible for
pharmacological thromboprophylaxis [15]. To this aim,
Korhana et al. have developed and prospectively vali-
dated a risk assessment model that stratifies cancer pa-
tients to high, moderate or low risk for VTE prior to
chemotherapy initiation [16].
Thrombosis is a multifactorial disease occurring when
the Virchow’s triade (blood hypercoagulability, vessel
wall lesion and alteration of blood flow) is fulfilled.
However, current risk assessment models for VTE in
cancer patients are restricted to some clinical risk factors
and are missing the evaluation of blood borne hyperco-
agulability, although this is one of the basic components
of Virchow’s triad. The expression of tissue factor (TF)
by cancer cells as well as the formation of procoagulantmicroparticles derived from activated platelets, are piv-
otal events leading to enhanced thrombin generation in
patients with cancer (reviewed in [17-20]). TF-induced
activation of blood coagulation in cancer patients leads
to sustained thrombin generation and fibrin formation
[21]. The D-Dimers are degradation products of cross-
linked fibrin, indicating either enhanced fibrin formation
or activation of the fibrinolytic system, or increased
levels of fibrinogen and likely reflect the biological activ-
ity of cancer cells [22]. Increased concentration of D-
Dimers in plasma has been observed in patients with
breast, prostate or bowel cancer [23].
It has been reported that incorporation of biomarkers
of cellular or plasma hypercoagulability increases the
sensitivity of the risk assessment models to identify can-
cer patients at risk for VTE [24]. The aim of the present
study was to investigate the potential relation between
cancer-related characteristics and the biomarkers of
plasma and cellular hypercoagulability. The capacity of
thrombin generation in patients’ plasma, the concentra-
tion of procoagulant platelet-derived microparticles ex-
pressing phosphatidylserin (Pd-MP/PS+) in plasma, the
procoagulant phospholid (PPL) dependent clotting time
and D-Dimers were assessed in a cohort of women suf-
fering from breast cancer. These biomarkers of plasma
and cellular hypercoagulability were analyzed in relation
to the stage of the disease, the time elapsed since diag-
nosis and the administration of chemotherapy.Methods
Cancer patients
Out-patients with histologically proven breast cancer
were enrolled in the study from January to June 2012.
Patients were considered under chemotherapy if they
had received a chemotherapy cycle 21 days earlier. The
exclusion criteria were: age less than 18 years, recent
(<6 months) documented episode of VTE (deep venous
thrombosis and/or pulmonary embolism) or acute cor-
onary syndrome, confirmed pregnancy, major psychiatric
disorders, life expectancy less than 3 months, active anti-
coagulant treatment, recent (<3 months) hospitalization
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(<2 months).
Classification of the patients
Patients were classified for post hoc analysis according
to the tumor, node, metastases (TNM) system of stratifi-
cation: Local stage was defined by the absence of axillary
nodes and distant metastasis (TxN0M0). Regional stage
was defined by the presence of axillary node(s) and the
absence of distant metastasis (TxN +M0). The metasta-
sis stage was defined by the presence of one or more dis-
tant metastases (TxNxM+) [25]. Patients were also
stratified according to the presence or not of at least one
cardiovascular risk factor. Stratification according to
hormone positive or negative receptor breast carcinoma
was not possible since data were not available for all
patients.
Control group
The control group consisted of 30 age-matched healthy
women who did not have breast cancer and who were
not taking any medication for at least one month before
blood sampling. Healthy volunteers had normal pro-
thrombin time (PT) and activated partial thromboplastin
time (aPTT) and had no personal history of thrombotic
or hemorrhagic episodes. The values obtained in this
population, comparable in age to the breast cancer pa-
tients, were used to establish reference intervals for the
assays. All patients and healthy individuals gave written
informed consent for participation in the study.
Blood samples
Blood samples were obtained by traumatic puncture of
the antecubital vein, using a 20-gauge needle, and placed
into siliconized vacutainer tubes containing 0.129 mol/L
trisodium citrate (from Becton and Dickinson France) as
anticoagulant, in a ratio of nine parts of blood to one
part of citrate. Platelet poor plasma (PPP) was obtained
after double centrifugation of citrated whole blood for
20 minutes at 2000 g. Platelet-free plasma was prepared
immediately after blood sampling using a 2-step centri-
fugation procedure: initially at 1500 g for 15 minutes at
20°C to prepare platelet rich plasma and then at 13000 g
for 2 minutes at 20°C to prepare PFP. Samples were ali-
quoted and frozen at −80°C until assayed. All measure-
ments were done in thawed plasma samples. All PPP
samples were from vein punctures performed for routine
evaluation of blood coagulation tests. Blood anticoagu-
lated with EDTA was used for the determination of
complete blood count. This study was approved by the
ethics committee of Tenon University Hospital and was
performed in accordance with the principles embodied
in the Declaration of Helsinki.Thrombin generation in plasma
Thrombin generation in PPP was assessed using the Cali-
brated Automated Thrombogram assay (CAT®, Diagnostica
Stago, France) as described by Hemker et al. [26]. Briefly
80 μl of PPP was added to 20 μl of PPP-reagent 5 pM®
(Thrombinoscope b.v., Maastricht, Netherlands), that is a
mixture of TF (5 pM final concentration in plasma) and
phospholipids (4 μM final concentration in plasma). Each
patient’s plasma was studied in duplicate. In a third well,
PPP reagent 5 pM® was replaced with the same volume of
Thrombin Calibrator® (Thrombinoscope bv, Maastricht,
Netherlands) to correct thrombin generation curves for
substrate consumption and the inner filter fluorescence ef-
fects. Thrombin generation was triggered with a 20 μl solu-
tion containing CaCl2 (16.7 mM final concentration) and
the fluorogenic substrate Z-Gly-Gly-Arg-AMC (417
pM final concentration). Fluorescence was measured
using a Fluoroscan Ascent®fluorometer (ThermoLabsys-
tems, Helsinki, Finland). Acquisition of thrombin gener-
ation parameters was performed using the appropriate
software (Calibrated Automated Thrombogram®bv, Maas-
tricht, Netherlands). Among thrombogram parameters we
analyzed the endogenous thrombin potential (ETP) that
reflects the integral thrombin activity, the Peak concentra-
tion of thrombin and the mean rate index (MRI), which
reflects the rate of the propagation phase of throm-
bin generation [calculated by the formula MRI = Peak/
(ttPeak – lag-time)].
Microparticle labelling and flow cytometry analysis
Platelet-derived microparticles were measured in platelet
free plasma using a flow cytometry assay as described by
Robert et al. [27]. Briefly, for Pd-MP/PS+ labelling, 30 μL
of fresh PFP was incubated with 10 μL of a solution of
phycoerythrin (PE) bound monoclonal antibody against
platelet glycoprotein IIb (CD41). For the detection of
phosphatidylserine expression by Pd-MP the plasma
samples were additionally spiked with 10 μL of fluoresce in
isothiocyanate (FITC) labelled recombinant human nnexin
V. Anti-CD41 monoclonal antibody was purchased from
BioCytex (Marseille, France). Human annexin -FITC kit
was obtained from AbCys (Paris, France). Concentration-
matched isotype antibodies (IgG1–PE, 15 ng/μL, clone
2DNP-2H11, from BioCytex) or Annexin V-FITC with
phosphate-buffered saline without calcium were used as
controls. Analyses were performed on Cytomics FC500
flow cytometer (Beckman-Coulter, Villepinte, France). To
limit background noise from dust and crystals, the instru-
ment was operated using a 0.22 μm filtered sheath fluid
(IsoflowTM; Beckman-Coulter, France). The software
packages CXP ACQUISITION® and CXP ANALYSIS®
(Beckman-Coulter, France) were used for data acquisi-
tion and analysis, respectively. Standardization of the Pd-
MP protocol was done using a blend of mono-disperse
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of three diameters (0.5, 0.9 and 3 μm). Forward scatter and
side scatter parameters were plotted on logarithmic scales
to best cover a wide size range. Pd-MP were defined as sin-
gle positive CD41+ events. CD41 positivity was displayed
on single parameter histograms. Pd-MP/PS+ were defined
as dual-positive phosphatidylserine PS+/CD41 events as
displayed on dual-color fluorescence plots after staining
with annexin V-FITC and CD41-PE. In each studied sam-
ple 30 μl of counting beads with an established concentra-
tion close to 1000 beads/μl (Flow CountTMFluorosphores
Beckman-Coulter) were added in order to express counts
as absolute numbers of microparticles per microliter of
PFP. All plasma samples were assessed for Pd-MP within
one week after blood collection and after one cycle of
freezing /thawing. Application of the same experimental
conditions reduced the impact of the eventual error intro-
duced by the freezing/thawing on Pd-MP concentration.
Assessment of procoagulant phospholipid dependent
activity in plasma
Procoagulant phospholipid-dependent clotting time (PPL)
was measured in thawed PPP using the factor Xa - based
coagulation assay (PPL clotting time) STA®Procoag-PPL,
(DiagnosticaStago, Asnières, France) in which shortened
clotting times are associated with increased levels of pro-
coagulant phospholipids. The PPL clotting time was per-
formed according to the manufacturer’s instructions on a
STA®-R analyser.
D-Dimers
The concentration of D-Dimers in platelet poor plasma
was determined using the enzyme linked fluorescent assay
on a mini VIDAS system (bio-Merieux, Paris, France).
The assay employs a quantitative sandwich enzyme im-
munoassay technique combining a bound anti-D-Dimer
monoclonal immunoglobulin with an unbound enzyme
labeled anti-D-dimer monoclonal immunoglobulin. Re-
sults are reported in ng/mL of fibrinogen equivalent units.
According to manufacturer’s instructions, D-Dimers con-
centrations equal or lower than 500 ng/ml were consid-
ered as normal.
Routine biochemical and hematological assessment
Blood samples were also obtained for the assessment of
transaminase levels (ASATand ALAT), CRP, urea and cre-
atinine. Routine hemogram parameters as well as pro-
thrombin time (expressed as percentage of prothrombin)
and activated partial thromboplastin time (expressed as
ratio of patients/control values), were also analyzed. Rou-
tine hematological and biochemical measurements were
performed with standardized assays existing in the central
hematological and biochemical hospital laboratory.Statistical analysis
The potential changes of the studied biomarkers in the
group of breast cancer patients versus the control group
as well as in the subgroups of patients stratified accord-
ing to the stage of the cancer, the chemotherapy and the
time since the diagnosis were unknown. Consequently,
determination of the sample size according to a power
analysis based on the predicted differences of the studied
biomarkers in function of cancer related variables was
not feasible. For this reason, the sample size for each
one of the main groups (patients and controls) and con-
sequently for the subgroups of patients, was based on
the minimum number of individuals required in order to
apply the statistical tests which were used. Continuous
variables are expressed by means ± standard deviation.
In the groups of patients and controls comparisons be-
tween continuous variables were performed using Stu-
dent’s t-test when they were normally distributed and
Mann–Whitney test when they were abnormally distrib-
uted and when variables had a coefficient of variation
higher than 100%. One way ANOVA test was used to
determine the possible differences among subgroups of
patients (defined according the stage of cancer the pres-
ence of chemotherapy and the time since diagnosis and
controls). Homogeneity of the values was tested with
Levene test for equality of errors in variances and nor-
mality of residues was verified by the Shapiro-Wilk test.
The Kruskal-Wallis test was used when no homogeneity
was documented. For significant variables post hoc LSD
test was applied to compare differences between groups.
Multiple comparisons and Spearman coefficient correla-
tions were calculated. When appropriate, the upper and
lower normal limits (UNL and LNL respectively) for the
studied biomarkers of hypercoagulability were defined
respectively as upper and lower limit of the 95% confi-
dence interval (CI) of normal values obtained by per-
forming the corresponding tests in the control group
(healthy volunteers). Thrombin generation was consid-
ered as increased when at least one of the studied pa-
rameters (ETP, Peak or MRI) showed a value higher than
the UNL. Two-sided p-value <0.05 was considered sig-
nificant. Statistical analysis was performed using SPSS
20.0 (SPSS Inc., Chicago, IL).
Results
Patients characteristics
A total of 62 women with breast cancer were included
in the study. The mean age of the breast cancer group
and the control group was not significantly different
(52 ± 11 years and 55 ± 10 years respectively; p > 0.05).
Basic hematological parameters in the breast cancer
group were within the normal range and not signifi-
cantly different compared to the control group. The
body mass index was also not significantly different
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normal in 8 our 62 patients (12%).
Patients were stratified in subgroups according to the
stage of the disease as follows: 13 had a local stage, 29
had a regional stage and 20 had metastatic disease. In
the subgroup with metastatic stage disease, 95% had
bone metastasis and 40% also had liver or lung metasta-
ses. Age, BMI and basic hematological parameters were
not significantly different among these subgroups, as
well as between each subgroup and the control group.
Patients were also stratified to those who were on active
chemotherapy (n = 41).
Patients were also stratified according to the time
elapsed since the diagnosis of cancer: <6 months (n = 27)
and more than 6 months (n = 35; of home 10 patients
were diagnosed 6–12 months, 13 patients were diag-
nosed 12–36 months and 12 patients were diagnosed
more than 36 months before the inclusion in the study).
Invasive ductal carcinoma of the breast was diagnosed in
90% of patients. Curative surgery was performed in 82%
of the patients included in the study. All surgicalTable 1 Demographic data, clinical characteristics and routine





Age (year) 55 ± 10 52 ± 11
BMI (Kg/m2) 27 ± 6 28 ± 4.7
Hemoglobin (g/dL) 11.6 ± 2 11.5 ± 1.5
Leukocytes (109/L) 7.3 ± 1.8 7.1 ± 4.8
Platelets (109/L) 270 ± 62 242 ± 96
PT (% of prothrombin) 100 ± 8 92 ± 8.3
aPTT ratio 1 ± 0.2 0.9 ± 0.06
Fibrinogen (g/L) 3.9 ± 0.6 4.4 ± 1.2
CRP (mg/L) - 14.5 ± 50
ALAT (IU/L) - 25 ± 13
ASAT (IU/L) - 36 ± 23
Creatinine (μmol/L) - 65 ± 17
Urea (mg/dL) - 5 ± 2
Time since diagnosis (n)
0-6 months 27
6-12 months 10
12-36 months - 13
> 36 months 12
Cardiovascular risk factors (n)
-Hypertension no 14
-Varicose veine no 8
-Hyperlipidemia no 4
-Diabetes no 6
Data are presented as mean ± sd.procedures were completed at least 2 months before en-
rolment. In 42 out of 62 patients (67%) at least one car-
diovascular risk factor was present. Demographic and
clinical characteristics of the studied groups are summa-
rized in Table 1.
Thrombin generation in breast cancer patients
Thrombin generation was significantly increased in breast
cancer patients as compared to the control group (Table 2).
The MRI was significantly higher in the group of patients
as compared to the control group (159 ± 47 nM/min ver-
sus 109 ± 33 nM/min respectively; p < 0.001). The Peak
was also higher in cancer patients as compared to the con-
trol group (341 ± 65 nM versus 288 ± 48 nM, respectively;
p = 0.001). The ETP was not significantly different between
the cancer group and the control group (1531 ± 337 nM.
min versus 1498 ± 225 nM.min).
The distribution of the individual values of thrombo-
gram parameters in cancer patients and controls is shown
in Figure 1. Representative thrombograms of patients with







53 ± 10 54 ± 11 49 ± 13
29.6 ± 4.7 27.6 ± 4.2 27.7 ± 5.6
11.2 ± 1.1 11.8 ± 1.4 11.3 ± 1.8
7.2 ± 2.4 7.1 ± 2.8 7.1 ± 5
262 ± 65 264 ± 98 198 ± 98
94 ± 6 95 ± 7 89 ± 11
0.9 ± 0.05 0.9 ± 0.06 0.9 ± 0.08
4 ± 0.8 4.7 ± 1.4 4.4 ± 1.1
32 ± 99 7 ± 20 10 ± 15
30 ± 16 24 ± 10 25 ± 15
31 ± 18 34 ± 17 43 ± 32
67 ± 23 67 ± 17 62 ± 13









Table 2 Biomarkers of cellular and plasma hypercoagulability in patients and controls
Control group
(n = 30) (95% CI)
Breast cancer group (n = 62)
All patients (n = 62) (95% CI) Local stage (n = 13) (95% CI) Regional stage (n = 29) (95% CI) Metastatic stage (n = 20) (95% CI)
MRI (nM/min) 109 ± 33 (96,5–121) 159 ± 47** (139–168) 172 ± 55§* (138–205) 146 ± 56§ (122–168) 162 ± 49** (126–180)
Peak (nM) 288 ± 48 (269–305) 341 ± 65* (323–365 369 ± 75** (323–414) 334 ± 90§§ (301–371) 343 ± 69§ (306–370)
ETP (nM.min) 1498 ± 225 (1413–1581) 1531 ± 337 (1448–1623) 1626 ± 332 (1424–1826) 1499 ± 374 (1366–1656) 1515 ± 285 (1369–1650)
Pd-MP (/μL) 756 ± 429 (650–1100) 10015 ± 8223§§ (7890–12138) 9370 ± 7724 (4702–14038) 7847 ± 6479*** 5334–10359) 13650 ± 9864 (8895–18404)
Pd-MP/PS+ (/μL) 695 ± 361 (550–1020) 9698 ± 7931§§ (7649–11746) 9115 ± 7428 (4626–13604) 7570 ± 6241*** (5150–9991) 13231 ± 9512 (8646–17816)
PPL (sec) 72.8 ± 9.9 (59–66) 43,5 ± 10,3 (41–46) 45 ± 10,2 (39–51) 44,3 ± 9,8 (40–48) 41,3 ± 11,3$ (35–47)
D-Dimers (ng/ml) 230 ± 50 (279–340) 1250 ± 1773 (767–1648) 605 ± 499*** (303–907) 1123 ± 1429 (503–1572) 1853 ± 2497 (703–3154)
Values are depicted as mean ± sd. The 95% Confidence Interval of the mean (95% CI) is also shown.

















Figure 1 Distribution of individual values of thrombin generation rate (frame A), Peak of thrombin (frame B) and ETP (frame C) in the control
group (open cycles) and in the group of patients (dark cycles).
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47 patients (76%). The Peak was higher than the UNL in
42 patients (68%). The ETP was higher than the UNL in 25
patients (40%). Among patients with high thrombin gener-
ation 21 (33%) had the three parameters of thrombogram
(MRI, Peak and ETP) higher than the UNL. In 21 patients
(33%) the MRI and the Peak was higher than the UNL.
Influence of stage, time and chemotherapy on thrombin
generation
In any stage of the breast cancer (local, regional and
metastatic) thrombogram parameters were significantly
increased as compared to the control group (Table 2).
Thrombin generation was significantly higher in patients
with newly diagnosed breast cancer (<6 months) as
compared to those in whom the time elapsed since the
diagnosis was more than 6 months. Similarly thrombin
generation in the subgroup of newly diagnosed patients
(<6 months) on chemotherapy was significantly higher
as compared to those on active chemotherapy in whom
the time elapsed since the diagnosis of breast cancer was
more than 6 months (Table 3, Figure 3).
No significant differences of thrombogram parameters
were observed between subgroups of patients with local or
regional stage of the disease. The subgroup of patients with
metastatic stage was not analysed because it included only
4 newly diagnosed patients (less than 6 months) and 10 pa-
tients on active chemotherapy. Thus the impact of the
metastatic stage on thrombin generation was confounded.
Procoagulant platelet-derived microparticles in breast
cancer patients
In the control group the concentration of Pd-MP and
Pd-MP/PS+ was 756 ± 429/μl and 695 ± 361/μL respect-
ively. In the breast cancer group Pd-MP and Pd-MP/PS+
were significantly increased (p < 0.001) compared to theFigure 2 Representative thrombograms from a healthy individual
(a) and four patients with high thrombin generation (b, c, d, e).control group (Table 2). The concentration of Pd-MP
and Pd-MP/PS+ was higher than the UNL in 97% and
93% of patients respectively. Accordingly, the PPL clot-
ting time was significantly shorter in patients as com-
pared to the control group (43.5 ± 10 sec versus 72.8 ±
9.9; p = 0.03). The PPL clotting time was significantly
correlated with both Pd-MP and Pd-MP/PS+ (r2 = 0.7;
p < 0.0001). In 51 patients (82%) the PPL clotting time
was shorter than the LNL of the assay.
Influence of stage, time and chemotherapy on platelet-
derived microparticles
There was no significant difference in Pd-MP or Pd-MP/
PS+ between the subgroups of patients with local or re-
gional stage of cancer. Patients with metastatic disease
had significantly higher levels of Pd-MP and Pd-MP/PS+
compared to those with regional stage (Table 2).
The concentration of Pd-MP and Pd-MP/PS+ was not
influenced by the time since the diagnosis of the breast
cancer (Table 3). The stratification of each subgroup ac-
cording to the administration of chemotherapy did not
show any significant difference between the subgroups
(Table 3). The PPL clotting time, similarly to Pd-MP,
was not influenced by chemotherapy and time since
diagnosis but it was significantly shorter in patients with
metastatic disease as compared to those with local stage
(Table 2).
D-Dimer levels in breast cancer patients
The concentration of D-Dimers was significantly in-
creased in cancer patients (1250 ± 1773 ng/ml) compared
to the control group (230 ± 50 ng/ml; p < 0.05). The con-
centration of D-Dimers tended to increase in advanced
stages of the disease (Table 2). However no significant dif-
ference was observed between the subgroups of patients
with local and regional stage (605 ± 499 ng/ml versus
1123 ± 1429 ng/ml; p > 0.05). The concentration of
D-Dimers in patients with metastatic stage (1853 ±
2497 ng/ml) was significantly higher as compared to that
in patients with local stage (p = 0.049). The concentration
of D-Dimers in patients with regional stage was not sig-
nificantly different as compared to patients with meta-
static stage (Figure 4). The analysis of the data from the
subgroup of the patients on chemotherapy showed a simi-
lar trend of elevation of D-Dimers in parallel with the
stage of the cancer.
In patients with localized disease receiving chemother-
apy, the concentration of D-Dimers was significantly lower
(410 ng/mL, range 220–1230 ng/mL) compared to patients
on chemotherapy for metastatic disease (1920 ng/mL,
range, 242–6547 ng/mL, p = 0.033). The time since diag-
nosis of cancer did not show any significant influence on
D-Dimer levels in the subgroup of patients having
chemotherapy.
Table 3 Thrombogram parameters and Pd-MP levels in all patients and in patients on chemotherapy according to the
time since the diagnosis (less than 6 months or more)
All patients (n = 62) Patients on chemotherapy (n = 41)
0-6 months (n = 27) >6 months (n = 35) 0-6 months (n = 20) >6 months (n = 21)
MRI (nM/min) 160 ± 60* 153 ± 48 161 ± 55* 148 ± 52
Peak (nM) 353 ± 92* 336 ± 70* 362 ± 73* 324 ± 74
ETP (nM.min) 1593 ± 340* 1483 ± 332 1627 ± 335* 1402 ± 327
Pd-MP (/μL) 10098 ± 7057 9946 ± 9175 10054 ± 7769 9026 ± 7469
Pd-MP/PS+ (/μL) 9731 ± 6821 9671 ± 8841 9695 ± 7488 8793 ± 7265
PPL (sec) 43,9 ± 10,8 43,3 ± 10,1 43,3 ± 12,3 44,7 ± 10,8
Values are mean ± sd. *p < 0,05 versus >6 months.
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plasma was higher than the age adapted upper normal
cut-off level. In 29 patients (46%) the concentration
of D-Dimers and at least one parameter of thrombo-
gram were higher than the UNL of the correspon-
ding test.Cardiovascular risk factors and markers of cellular and
plasma hypercoagulability in breast cancer patients
Thrombin generation, PPL clotting time and the concen-
tration of Pd-MP, PdMP/PS+ were not significantly dif-
ferent between the subgroup of patients with at least
one risk factor of cardiovascular disease compared to
those who did not have any cardiovascular risk factor. In
contrast, the concentration of D-Dimers was signifi-
cantly higher in patients with breast cancer who had
at least one cardiovascular risk factor as compared to
those who did not have any cardiovascular risk factor
(Table 4).Figure 3 Impact of the interval since the diagnosis (shorter of
longer than 6 months) on the ETP in patients on chemotherapy.Correlation of cellular and plasma markers of
hypercoagulability with routine hematological and
biochemical parameters
Age and BMI of patients did not correlate with any of
the studied biomarkers of hypercoagulability. Among
thrombogram parameters the Peak and the ETP were
significantly correlated with the CRP (r = 0.3; p = 0.028
and 0.019 respectively). The peak was also correlated
with the ASAT levels (r = 0.3; 0 = 0.03).
The concentration of D-Dimers was inversely correlated
with Hb (r = 0.52; p < 0.0005) and positively correlated
with the concentration of transaminases. In addition, alka-
line phosphatase was correlated with the concentration of
D-Dimers (r = 0.38; p < 0.005). The levels of D-Dimers did
not correlate with creatinine, urea and CRP.
The concentration of Pd-MP and Pd-MP/PS+ was in-
versely correlated with Hb (r = −0.3; p = 0.01) and posi-
tively correlated with the platelet count (r = 0.3; p = 0.02).
All the other hematological and biochemical parameters
did not correlate with thrombin generation parametersFigure 4 Impact of the stage of breast cancer on the conentration
of D-Dimers.
Table 4 Analysis of the impact of cardiovascular risk
factors on the biomarkers of cellular and plasma
hypercoagulability in patients with breast cancer
Total population of patients (n = 62)
CV RF (n = 21) No CV RF (n = 41)
MRI (mM/min) 134 ± 51 167 ± 51
Peak (nM) 317 ± 89 357 ± 72
ETP (mM.min) 1490 ± 346 1552 ± 335
Pd-MP (/μL) 8133 ± 6480 10955 ± 8893
Pd-MP/PS+ (/μL) 7896 ± 6328 10599 ± 8552
PPL (sec) 42 ± 10 44 ± 11
D-dimers (ng/ml) 1190 ± [440–1750] 540 ± [280–830]
CV RF: Cardiovascular risk factors.
Pd-MP: Platelet derived microparticles.
Pd-MP/PS+: Platelet derived microparticles expressing phosphatidylserin.
PPL: Procoagulant phospholipid dépendent clotting time.
MRI: Mean rate index of the propagation phase.
ETP: Endogenous thrombin generation.
*p = 0,05 versus No CV RF.
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eration parameters was correlated with the concentration
of D-Dimers or Pd-MP or with aPTT or PT.
Discussion
The present study demonstrates that blood hypercoagu-
lability in breast cancer patients is consisted of cellular
and plasma components and is characterized by marked
increase of procoagulant Pd-MP, enhanced thrombin
generation and increased degradation of fibrin. The stage
of the disease, the administration of chemotherapy and
the time elapsed since the diagnosis, have a significant
but variable impact on the cellular and plasma compo-
nents of hypercoagulability.
Almost all breast cancer patients showed high levels of
procoagulant Pd-MP and short PPL clotting time in
plasma. Thus, in patients with breast cancer, platelet ac-
tivation leading to the release of microparticles express-
ing phosphatidylserine is a principal characteristic of
blood borne hypercoagulability. This finding is in ac-
cordance with previous studies which showed that breast
cancer patients treated with chemotherapy or receiving
adjuvant endocrine therapy have increased numbers of
Pd-MP and a high microparticle-dependent thrombin
generation [28]. Our study shows that the increase of
Pd-MP is related to the underlying cancer rather than to
the anticancer treatment. Indeed, the stage of the disease
has a significant influence on the concentration of the
procoagulant Pd-MP and the PPL clotting time. Patients
with metastatic disease had significantly higher con-
centrations of Pd-MP and shorter PPL clotting time
compared to those with localized stage. Interestingly,
chemotherapy did not induce any significant change on
the concentration of Pd-MP or the PPL clotting time.These findings are in accordance with previous studies
[29-32] and support the hypothesis that Pd-MP concen-
tration and the PPL clotting time are biomarkers that re-
flect the close association between the burden of cancer
cells and platelets. Whether the release of procoagulant
microparticles by platelets stems from the direct inter-
action of platelets with breast cancer cells or is the con-
sequence of an inflammatory reaction triggered by
cancer merits further investigation. In favor of the
former hypothesis is that most of the patients in our
study showed CRP levels within the normal range. In
addition, no correlation was found between Pd-MP or
PPL-clotting time and CRP. The concept that platelet
activation is a dominant phenomenon in cancer is sup-
ported by several recent studies conducted in patients
with other types of cancer and may have therapeutic im-
plications in the management of cellular derived hyper-
coagulability and cancer [33-36].
Platelet-derived microparticles manifested significant
procoagulant activity as documented by the almost lin-
ear, inverse correlation between the concentration of
both Pd-MP and Pd-MP/PS+ with the PPL clotting time.
However, neither Pd-MP nor PPL-clotting time was
correlated with thrombin generation. In our study,
thrombogram-thrombinoscope assay was performed in
platelet poor plasma using 5 pm of TF and a saturating
concentration of procoagulant phospholipids (4 μM).
Preliminary experiments from our group showed that in
these experimental conditions, the thrombogram assay is
not sensitive to the procoagulant activity of microparti-
cles present in the plasma samples (data not shown).
Consequently, the two settings of tests describe different
components of hypercoagulability; the cellular and the
plasma one.
Thrombin generation was significantly increased in pa-
tients with breast cancer as compared to the control
group. About 76% of patients had the mean rate index
(MRI) of the propagation phase of thrombin generation
higher than the upper normal limit showing that the in-
crease of thrombin generation is also a major element of
the hypercoagulability in breast cancer. The present
study documents that a significant cellular and plasma
hypercoagulability occurs within the first six months
from the diagnosis of breast cancer. Indeed, the increase
of thrombin generation was marked in patients diag-
nosed with cancer within less than 6 months from the
inclusion as compared to those to whom the time
elapsed since the diagnosis of cancer was longer than
6 months. In addition, thrombin generation was signifi-
cantly increased in patients with recently diagnosed can-
cer who were on active chemotherapy as compared to
those who were on chemotherapy while the cancer was
diagnosed in an interval longer than 6 months from the
inclusion. These data lead to the conclusion that during
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and chemotherapy are combined stimuli of cellular
and plasma hypercoagulability. The Vienna Cancer and
Thrombosis Study (CATS), which prospectively evalu-
ated the capacity of biomarkers of hypercoagulability to
detect the risk of VTE in cancer patients, showed that
high thrombin generation is an independent risk factor
for VTE [37]. The data presented herein underline the
presence of significant increase of thrombin generation
and enhanced platelet activation during the first six
months after the diagnosis of breast cancer. This period
is characterized in breast cancer patients by a substan-
tially increased risk of VTE [12,38-43]. The subgroup
analysis failed to demonstrate an increase of thrombin
generation in patients with metastatic disease versus to
those without metastasis; although this was the case for
the Pd-MP. This is probably due to the heterogeneity of
the subgroup of patients with metastasis. This subgroup
was composed by a small number of patients recently di-
agnosed with cancer and also by a small number of pa-
tients on active chemotherapy. As mentioned above, the
time since the diagnosis inferior than six months and
the administration of chemotherapy are major determi-
nants for the increase of thrombin generation. Conse-
quently the composition of the subgroup of patients
with metastatic disease was a confounder for the evalu-
ation of the impact of the stage on thrombin generation.
The presence of cardiovascular risk factors was not asso-
ciated with any significant impact on either thrombin
generation or the concentration of Pd-MP and the PPL
clotting time. This finding further supports the concept
that the increase of Pd-MP concentration and the en-
hancement of thrombin generation are related to the
characteristics of the cancer (i.e. time since diagnosis,
stage and active chemotherapy). The poor correlation
between Pd-MP and the studied biochemical parameters
of inflammation, renal and liver function further en-
hances the assumption that platelet related hypercoa-
gulability is closely associate with cancer. Thrombin
generation showed also a weak correlation with CRP
and liver function. In the majority of the patients these
markers were within the normal range. Thus plasma hy-
percoagulability in the studied cohort of breast cancer
patients also stems from the interactions of cancer cells
with plasma and the impact of chemotherapy rather
thanfrom an inflammatory state.
Breast cancer patients also showed enhanced fibrin
degradation documented by the significant increase of
D-Dimers concentration in patients’ plasma as compared
to healthy age-matched individuals. In 59% of patients
D-Dimers concentration was higher than the upper nor-
mal limit. The D-Dimers concentration in patients with
metastatic disease was higher as compared to that in pa-
tients with localized cancer. The concentration of D-Dimers did not correlate with the Pd-MP concentration,
the PPL clotting time or the enhancement of thrombin
generation. In 46% of patients a combined increase of
D-Dimers and thrombin generation was observed docu-
menting a dissociation between these biomarkers which
apparently measure different aspects of the interactions
between breast cancer cells, blood coagulation, platelets
and fibrinolysis. The elevation of D-Dimers, particularly
in the advanced stage of the disease, is in accordance
with previous studies which demonstrated that the aug-
mentation of D-Dimers might be in part a reflection of
ongoing fibrinogen metabolism within the actively re-
modeled tumor stroma [44]. The increase of D-Dimers
is related to the clinically measured growth rate of breast
cancer, the tumor volume, the progression rate and the
survival in patients with metastatic breast cancer [44].
Tumor cells possess strong procoagulant activities that
induce local activation of the coagulation system and de-
position of fibrin, which has an important role in the
formation of tumor stroma and hematogenous spread of
tumor cells [45]. The Vienna Cancer and Thrombosis
Study (CATS) showed that enhanced activation of co-
agulation and fibrinolysis, as reflected by high levels of
D-dimers, is independently associated with an unfavor-
able prognosis in patients with solid cancers and is not
necessarily mediated by the increased risk of VTE [22].
Our data, being in accordance with these evidence allow
to conclude that in breast cancer patients the D-Dimers
is a biomarker which is related with a global biological ac-
tivity of cancer cells which is not restricted to plasma hy-
percoagulability. Noteworthy in our study, the presence of
cardiovascular risk factors was linked with a significant in-
crease of the concentration of D-Dimers revealing that the
D-Dimers is a less specific biomarker for cancer induced
hypercoagulability.
The identification of breast cancer patients at risk of
VTE and the optimization of thromboprophylaxis is a
puzzling exercise because VTE risk varies according to
the type of cancer and is potentially influenced by its
evolution, the histology and the localization of the can-
cer, the duration and the intensity of chemotherapy or
other adjuvant treatments. The development of Risk As-
sessment Models (RAM) for VTE risk stratification
adapted for cancer patients and their prospective clinical
validation is required. Such a RAM - focused on cancer
patients receiving chemotherapy - has been proposed
and prospectively validated by Khorana [16]. This model
includes some clinical risk factors such as the site of can-
cer, the body mass index, the increased pre-chemotherapy
platelet and leukocyte counts. However, other variables re-
lated to the malignant disease which contribute to the
VTE risk (i.e. the stage, the type of anticancer therapy
etc.) are lacking. In addition, the Khorana RAM does not
include breast cancer. The data from our study show that
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blood borne hypercoagulability which is influenced by the
stage of the disease, the time elapsed from the diagnosis
and the administration of chemotherapy. The weighted in-
corporation of the studied biomarkers of cellular and
plasma hypercoagulability in association with the clinical
characteristics of breast cancer and the other intrinsic risk
factors for VTE present in patients could formulate a new
specific RAM for breast cancer patients. To this aim a
prospective studied is needed.
Conclusions
The present study identified the most appropriate bio-
markers for the diagnosis of blood borne hypercoagula-
bility related to breast cancer. The concentration and
the procoagulant activity of Pd-MP are interconnected
with the biological activity and the overall burden of
cancer cells. Assessment of thrombin generation is re-
lated with both the procoagulant characteristics of breast
cancer andthe procoagulant effect of anticancer treat-
ment administration within 6 months after the diagnosis
of the disease. Thus the weighted incorporation of the
biomarkers of cellular and plasma hypercoagulabilty in
risk assessment models for VTE might lead to the elab-
oration of a breast cancer specific RAM with improved
predictive value.
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